A dose response study of oxitropium bromide in chronic bronchitis.

Peel, E.; Anderson, G. W.

doi:10.1136/thx.39.6.453

Cited by 23 publications

(8 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could reflect a transient hyperresponsiveness, although the overall increase in PEFR over the treatment period may be due to a learning effect on the measurement. The fact that oxitropium, a long-acting bronchodilator [21], failed to affect PEFR, supports this view. An alternative explanation, is that a reduction in PEFR without a corresponding decrease in FEV1 may suggest an extrathoracic airway obstruction, which has been previously observed during URTI [3], and this would not be expected to respond to bronchodilator therapy.…”

Section: Resultsmentioning

confidence: 69%

The effect of anticholinergic bronchodilator therapy on cough during upper respiratory tract infections.

Lowry¹,

Wood²,

Higenbottam³

1994

Brit J Clinical Pharma

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 69%

The effect of anticholinergic bronchodilator therapy on cough during upper respiratory tract infections.

Lowry¹,

Wood²,

Higenbottam³

1994

Brit J Clinical Pharma

View full text Add to dashboard Cite

“…Thirty minutes after each inhalation, FVC and FEV1 were again measured. The doses of oxitropium bromide [8] and orciprenaline sulphate [9] and lung function measuring time were chosen to cause almost maximal bronchodilation by each drug according to the previous papers and this effect was confirmed in a preliminary study.…”

Section: Protocolmentioning

confidence: 99%

Relationship between cholinergic airway tone and serum immunoglobulin E in human subjects

Endoh¹,

Ichinose²,

Takahashi³

et al. 1998

Eur Respir J

View full text Add to dashboard Cite

It has recently been shown that immunoglobulin (Ig)E facilitates the cholinergic bronchoconstrictor pathway in human tissue in vitro. However, whether this occurs in humans in vivo has not been clarified. In this study, the bronchodilator responses were examined to inhalation of a submaximal dose of the anticholinergic agent oxitropium bromide (600 microg) in normal and allergic subjects with various levels of total serum IgE. Values of the forced expiratory volume in one second (FEV1) for all subjects were greater than 80% of predicted, but were negatively correlated with serum IgE levels (p<0.01). Oxitropium bromide inhalation induced an increase in FEV1 that was significantly greater in allergic rhinitis patients with high serum IgE (155+/-20 mL (mean+/-SEM), p<0.05) than in healthy subjects (64+/-21 mL) or those with allergic rhinitis but low serum IgE (82+/-21 mL, p<0.05). In contrast, the effects of the inhaled beta2-adrenergic agent orciprenaline sulphate (2.25 mg) were not significantly different among the three groups. In conclusion, higher serum immunoglobulin E levels were correlated with lower values of the forced expiratory volume in one second, and anticholinergic agents, but not beta2-adrenergic agents, caused more pronounced bronchodilation in subjects with high than in those with low immunoglobulin E levels. These data suggest that serum immunoglobulin E may be one of the factors that determine the airway tone, possibly via cholinergic mechanisms.

show abstract

“…It has been reported to have a more protracted duration of action than ipratropium bromide and fenoterol. OTB seems to be of most benefit in patients with COPD, in whom it can produce symptomatic benefits, improvement in exercise tolerance and nocturnal symptoms [1][2][3][4][5][6]. Vagally induced mucociliary clearance is not impaired by OTB [7].…”

mentioning

confidence: 99%

Dose-response study of oxitropium bromide inhaled as a nebulised solution

Stappaerts

Schil

Veken

1994

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Twelve patients suffering from partially reversible chronic obstructive pulmonary disease (COPD) took past in a single blind, randomised, 4-way cross-over trial to determine the optimal dose and duration of action of the anticholinergic agent oxitropium bromide (OTB) inhaled as a nebulised solution. Single doses of 500, 1000, 1500 and 2000 micrograms nebulised OTB were compared during a 6 hour-observation period. Lung function test results indicated that 500 and 1000 micrograms OTB only induced slight bronchodilatation, whereas 1500 and 2000 micrograms OTB produced a significantly greater increase in mean FEV1 compared to 500 micrograms. There was a trend for 2000 micrograms to be superior to 1000 micrograms, but 2000 micrograms and 1500 micrograms were not significantly different. Significant bronchodilatation (> 15% rise in FEV1 from baseline) persisted for 6 h after 1500 micrograms. A significant decrease in airway resistance (Raw) was observed following inhalation of 2000 micrograms. The mean decrease in Raw was 33% after 30 min, 20% after 4 h and 12% after 6 h. In this trial, 2000 micrograms OTB administered by an ultrasonic nebuliser was the optimal dose, but a satisfactory result was also obtained with 1500 micrograms.

show abstract

A dose response study of oxitropium bromide in chronic bronchitis.

Cited by 23 publications

References 2 publications

The effect of anticholinergic bronchodilator therapy on cough during upper respiratory tract infections.

The effect of anticholinergic bronchodilator therapy on cough during upper respiratory tract infections.

Relationship between cholinergic airway tone and serum immunoglobulin E in human subjects

Dose-response study of oxitropium bromide inhaled as a nebulised solution

Contact Info

Product

Resources

About